Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01 Clinical Trials Not Allowed)
This funding opportunity supports research on how mitochondrial function and aging are affected by HIV and substance use disorders, aiming to develop targeted therapies for individuals facing these challenges.
Description
The NIH’s funding opportunity (RFA-DA-26-009) supports R01 research projects focused on understanding the mitochondrial mechanisms that contribute to neuropathology and immune aging in individuals affected by HIV and substance use disorders (SUD). This research seeks to uncover protective and harmful pathways involving mitochondrial function that could lead to new therapeutic approaches to improve health outcomes in people aging with HIV and SUD. Clinical trials are not permitted under this grant.
Eligible applicants include public and private institutions of higher education, tribal organizations, government entities, nonprofits, for-profit organizations (excluding small businesses), and minority-serving institutions such as HBCUs and Hispanic-serving Institutions. Non-U.S. institutions are not eligible to apply directly but may be included as components in U.S.-based projects.
Applications are due by March 10, 2026, with archiving on April 15, 2026. There is no cost-sharing requirement, and specific funding limits are not disclosed. For further information, applicants should refer to the full NIH announcement or contact NIH Grants Information for assistance. This opportunity is suitable for institutions aiming to explore the intersection of aging, mitochondrial health, HIV, and addiction-related research.